NCT04717986View on ClinicalTrials.gov

Dapagliflozin Effects on Mayor Adverse Cardiovascular Events in Patients With Acute Myocardial Infarction (DAPA-AMI)

NACompletedINTERVENTIONAL
Enrollment

188

Participants

Timeline

Start Date

January 26, 2021

Primary Completion Date

June 30, 2022

Study Completion Date

June 20, 2023

Conditions
Acute Myocardial InfarctionCardiovascular MorbidityHeart FailureAngina, Unstable
Interventions
DRUG

Dapagliflozin 10Mg Tab

patients who meet the inclusion criteria will be randomized to receive dapagliflozin 10 mg every 24 hours for 12 months

DRUG

Placebo

patients meeting the inclusion criteria will be randomized to receive a placebo solution every 24 hours for 12 months

Trial Locations (1)

37260,

Unidad Medica de Alta Especialidad No. 1, Bajío, León

All Listed Sponsors
lead

Instituto Mexicano del Seguro Social

OTHER_GOV

NCT04717986 - Dapagliflozin Effects on Mayor Adverse Cardiovascular Events in Patients With Acute Myocardial Infarction (DAPA-AMI) | Biotech Hunter | Biotech Hunter